NO20044451L - Lav-doserings flytende entecavir-formuleringer og deres anvendelse - Google Patents

Lav-doserings flytende entecavir-formuleringer og deres anvendelse

Info

Publication number
NO20044451L
NO20044451L NO20044451A NO20044451A NO20044451L NO 20044451 L NO20044451 L NO 20044451L NO 20044451 A NO20044451 A NO 20044451A NO 20044451 A NO20044451 A NO 20044451A NO 20044451 L NO20044451 L NO 20044451L
Authority
NO
Norway
Prior art keywords
entecavir
low
liquid
formulated
mixture
Prior art date
Application number
NO20044451A
Other languages
English (en)
Inventor
Divyakant Desai
Danping Li
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20044451L publication Critical patent/NO20044451L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Flytende farmasøytiske blandinger blir beskrevet som inneholder en lav dose med forbindelsen entecavir. I en utførelse av den foreliggende oppfinnelsen er den flytende blandingen av entecavir en blanding klar til bruk som er formulert slik at den både er stabil og smaker bra. I en annen utførelse av den foreliggende oppfinnelsen blir den flytende blandingen av entecavir formulert fra en pulverblanding på det tidspunktet blandingen skal anvendes. De lavdoserte blandingene av entecavir kan også inneholde minst en komponent som velges ut fra et søtningsmiddel, konserverende middel, smakstilsetning, bufrende middel, eller enhver kombinasjon av disse. De flytende blandingene av entecavir kan også formuleres sammen med andre farmasøytisk aktive forbindelser.
NO20044451A 2002-04-08 2004-10-19 Lav-doserings flytende entecavir-formuleringer og deres anvendelse NO20044451L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37067402P 2002-04-08 2002-04-08
PCT/US2003/010371 WO2003086367A1 (en) 2002-04-08 2003-04-03 Low dose liquid entecavir formulations and use

Publications (1)

Publication Number Publication Date
NO20044451L true NO20044451L (no) 2004-11-04

Family

ID=29250568

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044451A NO20044451L (no) 2002-04-08 2004-10-19 Lav-doserings flytende entecavir-formuleringer og deres anvendelse

Country Status (22)

Country Link
US (1) US20030190334A1 (no)
EP (1) EP1492510A4 (no)
JP (1) JP2005528389A (no)
KR (1) KR20040099403A (no)
CN (1) CN1319517C (no)
AR (1) AR039388A1 (no)
AU (1) AU2003226259A1 (no)
BR (1) BR0309057A (no)
CA (1) CA2481092A1 (no)
EA (1) EA008102B1 (no)
EC (1) ECSP045349A (no)
HR (1) HRP20040893A2 (no)
MX (1) MXPA04009735A (no)
MY (1) MY131488A (no)
NO (1) NO20044451L (no)
NZ (1) NZ535535A (no)
PE (1) PE20040324A1 (no)
PL (1) PL372322A1 (no)
RS (1) RS88404A (no)
TW (1) TWI275392B (no)
WO (1) WO2003086367A1 (no)
ZA (1) ZA200407672B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7511139B2 (en) 2004-06-04 2009-03-31 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
CN1732944B (zh) * 2005-09-02 2013-05-08 海南中和药业有限公司 恩替卡韦分散片及其制备方法
US20070060599A1 (en) * 2005-09-09 2007-03-15 Dimarco John D Crystalline forms of [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
RU2381807C1 (ru) * 2008-07-18 2010-02-20 Алексей Глебович Одинец Противовирусное средство
CN101869569A (zh) * 2009-04-21 2010-10-27 李迪 即用型恩替卡韦组合物
EP2508172A1 (en) 2011-04-06 2012-10-10 Zentiva, a.s. Stable and uniform formulations of entecavir and preparation method thereof
UY34262A (es) 2011-08-16 2013-04-05 Gilead Sciences Inc Hemifumarato de tenofovir alafenamida, sus composiciones, método de preparación, métodos para tratar infecciones virales y su uso para preparar medi camentos
CN102908312B (zh) * 2011-11-10 2014-06-04 陈小花 抗乙肝病毒液体组合物
US8517850B1 (en) * 2012-12-11 2013-08-27 Cobra Golf Incorporated Golf club grip with device housing
KR101462018B1 (ko) * 2013-04-01 2014-11-19 썬시스템즈(주) 엔테카비르 함유 구강 붕해형 필름제제
CN103301071A (zh) * 2013-06-03 2013-09-18 北京阜康仁生物制药科技有限公司 一种稳定的恩替卡韦无糖型颗粒剂及其制备方法
JP2016527308A (ja) * 2013-08-06 2016-09-08 ドン クック ファーマシューティカル カンパニー リミテッド エンテカビル微小球及びこれを含む非経口投与用医薬組成物
EP3158998A4 (en) * 2014-06-20 2018-02-14 CTC Bio, Inc. Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
CN104083374A (zh) * 2014-07-18 2014-10-08 石家庄创建医药科技有限公司 一种恩替卡韦口服液组合物
CN109984996B (zh) * 2018-01-02 2022-01-18 扬子江药业集团有限公司 恩替卡韦口服溶液及其制备方法
CN108434096A (zh) * 2018-06-20 2018-08-24 广州大光制药有限公司 一种恩替卡韦口服溶液及其制备方法
EP3815704A4 (en) * 2018-06-29 2022-04-20 The Doshisha FORMULATION CONTAINING EMRICASAN

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489026A (en) * 1982-09-07 1984-12-18 The Upjohn Company Process for preparing solid unit dosage forms of ultra-low dose drugs
US5206244A (en) * 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
BR9916893A (pt) * 1999-01-12 2001-11-20 Smithkline Beecham Biolog Tratamento
RS51561B (sr) * 2000-02-29 2011-08-31 Bristol-Myers Squibb Co. Formulacija male doze entekavira i upotreba
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation

Also Published As

Publication number Publication date
EA200401298A1 (ru) 2005-02-24
KR20040099403A (ko) 2004-11-26
AU2003226259A1 (en) 2003-10-27
PE20040324A1 (es) 2004-05-29
CN1658844A (zh) 2005-08-24
WO2003086367A1 (en) 2003-10-23
MXPA04009735A (es) 2005-01-11
RS88404A (en) 2006-12-15
TWI275392B (en) 2007-03-11
EP1492510A1 (en) 2005-01-05
PL372322A1 (en) 2005-07-11
TW200306840A (en) 2003-12-01
JP2005528389A (ja) 2005-09-22
US20030190334A1 (en) 2003-10-09
NZ535535A (en) 2006-09-29
AR039388A1 (es) 2005-02-16
EP1492510A4 (en) 2006-01-11
ZA200407672B (en) 2005-10-12
EA008102B1 (ru) 2007-04-27
ECSP045349A (es) 2005-01-03
BR0309057A (pt) 2005-02-01
MY131488A (en) 2007-08-30
CN1319517C (zh) 2007-06-06
CA2481092A1 (en) 2003-10-23
HRP20040893A2 (en) 2005-02-28

Similar Documents

Publication Publication Date Title
NO20044451L (no) Lav-doserings flytende entecavir-formuleringer og deres anvendelse
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
NO20051102L (no) Sulfonylamino-eddiksyre-derivater
NO20064584L (no) Tetrahydropyridoindolderivater
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
EA200301275A1 (ru) Капсулы для ингаляции
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
NO20080801L (no) Aerosolformulering for inhalering av beta-agonister
IL179718A0 (en) Pharmaceutical composition containing irbesartan
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
TW200633978A (en) 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists
TW200514772A (en) Novel tetrahydropyridine derivatives
WO2004026836A8 (en) 1-pyridin-4-yl-urea derivatives
HUP0402077A2 (hu) Fungicid hatóanyag-kombinációk
WO2002070464A3 (en) Hydrazones and their therapeutic use
MX9400801A (es) Agentes colinergicos de oxima de tetrahidropiridinna o-substituidos estabilizados con almidon.
ATE324112T1 (de) Topische behandlung bei der mastalgie
WO2002024665A8 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
HRP20060040A2 (en) PURE D-(17α)-13-ETHYL-17-HYDROXY-18,19-DINORPREGN-4-ENE-20-YNE-3-ONE-3E- AND -3Z-OXIME ISOMERS, AS WELL AS PROCESS FOR THE SYNTHESIS OF THE MIXTURE OF ISOMERS AND THE PURE ISOMERS
WO2003075834A3 (en) Activated protein c formulations
MXPA05010957A (es) Derivados de ornitina activos farmaceuticamente, sales de amonio de los mismos y metodos para su preparacion.
TH63200A (th) สูตรผสมเอนทีคาเวอร์ชนิดของเหลวที่มีขนาดการใช้ยาต่ำ และการใช้
AU2566400A (en) Pharmaceutical combination of progesterone and folic acid

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application